UBS Group’s Pasithea Therapeutics KTTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $30.4K | Buy |
42,142
+37,805
| +872% | +$27.3K | ﹤0.01% | 6847 |
|
|
2025
Q1 | $5.64K | Sell |
4,337
-8,531
| -66% | -$11.1K | ﹤0.01% | 7655 |
|
|
2024
Q4 | $40.5K | Buy |
12,868
+6,301
| +96% | +$19.8K | ﹤0.01% | 6210 |
|
|
2024
Q3 | $35.6K | Buy |
6,567
+6,529
| +17,182% | +$35.4K | ﹤0.01% | 5838 |
|
|
2024
Q2 | $192 | Sell |
38
-570
| -94% | -$2.88K | ﹤0.01% | 7917 |
|
|
2024
Q1 | $4.41K | Buy |
+608
| New | +$4.41K | ﹤0.01% | 6456 |
|
|
2023
Q4 | – | Sell |
-4
| Closed | -$40 | – | 8338 |
|
|
2023
Q3 | $40 | Sell |
4
-342
| -99% | -$3.42K | ﹤0.01% | 7893 |
|
|
2023
Q2 | $3.39K | Buy |
+346
| New | +$3.39K | ﹤0.01% | 6555 |
|
|
2023
Q1 | – | Sell |
-637
| Closed | -$8.15K | – | 8753 |
|
|
2022
Q4 | $8.15K | Buy |
637
+364
| +133% | +$4.66K | ﹤0.01% | 7619 |
|
|
2022
Q3 | $7K | Sell |
273
-367
| -57% | -$9.41K | ﹤0.01% | 7775 |
|
|
2022
Q2 | $13K | Buy |
+640
| New | +$13K | ﹤0.01% | 6479 |
|
|
2021
Q4 | – | Sell |
-165
| Closed | -$10K | – | 9258 |
|
|
2021
Q3 | $10K | Buy |
+165
| New | +$10K | ﹤0.01% | 6858 |
|